Holen Sie sich die Stockscreener-App
11.07
0.69%
0.04
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Behavioral Patterns of KROS and Institutional Flows - Stock Traders Daily
Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell Microcap Value Benchmark Index - marketscreener.com
Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 3000E Index - marketscreener.com
Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell Microcap Index - marketscreener.com
Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Value-Defensive Index - marketscreener.com
Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Defensive Index - marketscreener.com
Nurix Therapeutics (NRIX) soars 16.4%: Is further upside left in the stock? - MSN
KROS Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBIT forward of Keros Therapeutics, Inc. – NASDAQ:KROS - TradingView
Price to sales forward of Keros Therapeutics, Inc. – NASDAQ:KROS - TradingView
Keros Therapeutics appoints Anne Prener to board of directors - Investing.com
Keros Therapeutics Appoints Anne Prener to Board - TipRanks
Keros Therapeutics appoints Anne Prener to board of directors By Investing.com - Investing.com UK
Anne Prener joins Keros Therapeutics (Nasdaq: KROS) board with equity package - Stock Titan
Keros Therapeutics Appoints Anne Prener to its Board of Directors - GlobeNewswire
Keros Therapeutics Inc (KROS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Keros Therapeutics Inc (KROS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Keros Therapeutics director Nima sells $28,166 in company stock - Investing.com UK
KROS,LBRX Dividends - Finviz
Keros Therapeutics Inc (KROS) Valuation: PE, PB & Fair Value Analysis - TradingKey
(KROS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Madison Avenue Partners LP Reduces Stock Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics Inc (KROS) Institutional Confidence - TradingKey
Keros Therapeutics Inc (KROS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Keros Therapeutics Inc (KROS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insider Buying: Jean Bienaime Acquires Additional Shares of Keros Therapeutics Inc (KROS) - GuruFocus
Keros Therapeutics Inc (KROS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Keros Therapeutics Inc (KROS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Keros Therapeutics (NASDAQ: KROS) director buys 1,000 shares under 10b5-1 plan - Stock Titan
Keros Therapeutics Inc (KROS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Insider Sell: Charles Newton Sells Shares of Keros Therapeutics Inc (KROS) - GuruFocus
Keros Therapeutics director Charles W. Newton sells $5,521 in shares - Investing.com
Keros Therapeutics director Charles W. Newton sells $5,521 in shares By Investing.com - Investing.com Nigeria
Keros Therapeutics Hits 52-Week Low at $9.69 Amidst Major Decline - Markets Mojo
Keros Therapeutics (KROS) director Newton sells 550 shares in planned trade - Stock Titan
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 99% Upside - TradingView
KROS Q1 2026 Earnings: Wider-Than-Expected Loss as Pipeline AdvancesNon-GAAP Earnings - newsline.com
[144] Keros Therapeutics, Inc. SEC Filing - Stock Titan
Keros Therapeutics director Nima sells $28,166 in company stock By Investing.com - Investing.com Nigeria
KROS: KER-065 targets muscle regeneration in DMD, with strong early data and a solid financial runway - TradingView
Director at Keros Therapeutics (NASDAQ: KROS) logs 2,625-share sale - Stock Titan
Director at Keros Therapeutics (KROS) sells 2,625 shares in Rule 10b5-1 trade - Stock Titan
Keros Therapeutics (KROS) Faces Selling Pressure as Shares Approach Key SupportATR Trailing Stop - newsline.com
How (KROS) Movements Inform Risk Allocation Models - Stock Traders Daily
Insider Sell: Alpna Seth Sells Shares of Keros Therapeutics Inc (KROS) - GuruFocus
Keros Therapeutics director granted RSUs and options | KROS Insider Trading - Stock Titan
Keros Therapeutics (KROS) director sells 2,625 shares under Rule 10b5-1 plan - Stock Titan
Keros Therapeutics (NASDAQ: KROS) director receives RSU and stock option awards - Stock Titan
Keros Therapeutics (KROS) grants RSUs and stock options to director - Stock Titan
Keros Therapeutics (NASDAQ: KROS) director receives RSUs and options grant - Stock Titan
Keros Therapeutics (KROS) director awarded RSUs and stock options - Stock Titan
Keros Therapeutics Stockholders Approve Directors and Governance Matters - TipRanks
Keros Therapeutics (NASDAQ: KROS) backs directors, auditor and pay - Stock Titan
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $21.83, Implies 107% Upside - TradingView
Keros Therapeutics CEO to Present at Goldman Sachs Conference - The Globe and Mail
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Keros Therapeutics CEO to speak at Goldman Sachs health conference - Stock Titan
Keros Therapeutics (Nasdaq: KROS) CEO to join Goldman Sachs healthcare fireside chat - Stock Titan
KROS Q1 2026 Earnings: EPS Miss of $1.21 as Pre-Revenue Biotech Continues Clinical InvestmentTech Earnings Analysis - newsline.com
1.95%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):